Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given an average recommendation of “Buy” by the twenty brokerages that are currently covering the stock, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is €82.75 ($96.22).

FME has been the topic of a number of recent research reports. Berenberg Bank set a €87.80 ($102.09) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Friday, December 7th. Independent Research set a €77.00 ($89.53) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Wednesday, October 31st. JPMorgan Chase & Co. set a €83.20 ($96.74) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Thursday, December 20th. Nord/LB set a €85.00 ($98.84) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Monday, November 5th. Finally, Sanford C. Bernstein set a €98.00 ($113.95) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a report on Monday, November 5th.

ETR:FME traded up €1.04 ($1.21) during mid-day trading on Friday, reaching €68.50 ($79.65). 1,113,162 shares of the company’s stock were exchanged, compared to its average volume of 704,197. Fresenius Medical Care AG & Co. KGaA has a one year low of €75.53 ($87.83) and a one year high of €93.82 ($109.09).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Ex-Dividend

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.